Patents by Inventor Wolfram Goessling
Wolfram Goessling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230053540Abstract: A method of treating an injury in an organ or tissue includes administering to a subject in need thereof an agent that modulates expression and/or activity of one or more genes involved in the regeneration and functional compensation of the tissue or organ in response to the injury.Type: ApplicationFiled: February 19, 2020Publication date: February 23, 2023Inventors: Alexander K. Shalek, Kellie Elizabeth Kolb, Chad Walesky, Wolfram Goessling
-
Patent number: 11040054Abstract: Provided herein are methods for the prevention and treatment of an abnormal tissue condition in the liver (e.g., liver cancer) of a subject, based on the administration of an inhibitor of a G protein-coupled estrogen receptor 1 (GPER1).Type: GrantFiled: November 14, 2017Date of Patent: June 22, 2021Assignee: The Brigham and Women's Hospital, Inc.Inventors: Wolfram Goessling, Saireudee Chaturantabut
-
Publication number: 20210077505Abstract: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.Type: ApplicationFiled: June 30, 2020Publication date: March 18, 2021Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATIONInventors: Leonard I. ZON, Trista E. NORTH, Wolfram GOESSLING
-
Patent number: 10736906Abstract: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.Type: GrantFiled: June 9, 2016Date of Patent: August 11, 2020Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATIONInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Publication number: 20190314399Abstract: Provided herein are methods for the prevention and treatment of an abnormal tissue condition in the liver (e.g., liver cancer) of a subject, based on the administration of an inhibitor of a G protein-coupled estrogen receptor 1 (GPER1).Type: ApplicationFiled: November 14, 2017Publication date: October 17, 2019Inventors: Wolfram Goessling, Saireudee Chaturantabut
-
Patent number: 10278990Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.Type: GrantFiled: March 15, 2013Date of Patent: May 7, 2019Assignees: Children's Medical Center Corporation, The General Hospital CorporationInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Patent number: 10272110Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.Type: GrantFiled: March 15, 2013Date of Patent: April 30, 2019Assignees: Children's Medical Center Corporation, The General Hospital CorporationInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Publication number: 20160354385Abstract: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.Type: ApplicationFiled: June 9, 2016Publication date: December 8, 2016Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATIONInventors: Leonard I. ZON, Trista E. NORTH, Wolfram GOESSLING
-
Patent number: 9402852Abstract: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.Type: GrantFiled: October 22, 2007Date of Patent: August 2, 2016Assignees: Children's Medical Center Corporation, The General Hospital CorporationInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Patent number: 9028811Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.Type: GrantFiled: March 27, 2012Date of Patent: May 12, 2015Assignees: Children's Medical Center Corporation, The General Hospital CorporationInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Publication number: 20140135396Abstract: The invention is directed to the treatment of patients at risk for liver damage due to the overingestion of acetaminophen by administering agents that increase hepatic levels of nitric oxide.Type: ApplicationFiled: July 4, 2012Publication date: May 15, 2014Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Wolfram Goessling, Andrew Cox, Trista North
-
Patent number: 8563310Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.Type: GrantFiled: March 27, 2012Date of Patent: October 22, 2013Assignees: Children's Medical Center Corporation, The General Hospital CorporationInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Patent number: 8551782Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.Type: GrantFiled: March 27, 2012Date of Patent: October 8, 2013Assignees: Children's Medical Center Corporation, The General Hospital CorporationInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Publication number: 20120189594Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.Type: ApplicationFiled: March 27, 2012Publication date: July 26, 2012Applicants: THE GENERAL HOSPITAL CORPORATION, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Publication number: 20120189592Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.Type: ApplicationFiled: March 27, 2012Publication date: July 26, 2012Applicants: THE GENERAL HOSPITAL CORPORATION, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Publication number: 20120189593Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.Type: ApplicationFiled: March 27, 2012Publication date: July 26, 2012Applicants: THE GENERAL HOSPITAL CORPORATION, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Patent number: 8168428Abstract: The present invention provides for compositions and methods for modulating hematopoietic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.Type: GrantFiled: April 26, 2007Date of Patent: May 1, 2012Assignees: Children's Medical Center Corporation, The General Hospital CorporationInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Publication number: 20110206781Abstract: Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells (HSC) and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro, ex vivo and/or in vivo. Also described are methods, compositions and kits related to making an expanded population of HSC and methods, compositions and kits related to using the expanded population of HSC. For example, HSC growth may be enhanced by contacting the nascent stem cells or HSC with an agent that stimulates the nitric oxide signaling pathway.Type: ApplicationFiled: May 28, 2009Publication date: August 25, 2011Inventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Publication number: 20110009370Abstract: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.Type: ApplicationFiled: October 22, 2007Publication date: January 13, 2011Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Publication number: 20090285786Abstract: The present invention provides for compositions and methods for modulating hematopoietic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.Type: ApplicationFiled: March 26, 2007Publication date: November 19, 2009Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Leonard I. Zon, Trista E. North, Wolfram Goessling